CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2020-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its third quarter 2020 financial results for the period ended September 30, 2020 . “We are pleased that both Ipsen Pharmaceuticals and Elevation Oncology
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 7, 2020-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its second quarter 2020 financial results for the period ended June 30, 2020 . “We are pleased by recent news releases from both Ipsen Pharmaceuticals and
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2020-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2020 financial results for the period ended March 31, 2020 . “We are pleased to report that we have significantly reduced our operating
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2020-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced receipt of $2.25 million in connection with the closing of a transaction in which the Company sold certain assets related to its preclinical
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 3, 2019-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “ Company ” or “ Merrimack ”), announced today that its Board of Directors (the “ Board ”) has adopted a Section 382 net operating loss rights plan (the “ Plan ”) and declared a dividend
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 3, 2019-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it received a $5 million milestone payment from Ipsen , triggered by Ipsen’s decision to progress the ongoing multi-part clinical trial evaluating ONIVYDE in patients with
Company Enters into Cooperation Agreement with Newtyn Management and Western Standard Independent Directors Noah Levy of Newtyn and Eric Andersen of Western Standard to Be Added to Merrimack Board, Effective Immediately Newtyn and Western Have Agreed to Vote for Merrimack Slate of Nominees for 2019
Dividend Amount is $1.496675 per Outstanding Share of Merrimack Common Stock and Will be Paid Today, as Previously Announced Company Provides Update on NOL Carryforwards; No Impairment as of July 24, 2019 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 5, 2019-- Merrimack Pharmaceuticals (Nasdaq: MACK)
Company’s Board has Taken Crucial Actions to Maximize Shareholder Value and Preserve More than $500 Million in Potential Future Milestone Payments Merrimack’s Current Plan Follows Comprehensive Strategic Review Conducted with Leading Healthcare Financial Advisory Firm and Provides Best Pathway for
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 16, 2019-- Merrimack Pharmaceuticals (Nasdaq: MACK) (the “Company” or “Merrimack”) announced today it is rescheduling its 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”) for October 17, 2019 . As a result, the record date for the 2019 Annual
